The development of a new genomic test has revolutionized disease diagnosis by detecting multiple pathogens in a single analysis. This innovative test has shown promising results in diagnosing neurological infections and respiratory viruses with high accuracy rates.
Researchers at the University of California–San Francisco (UCSF) have conducted a decade-long study on the new genomic test, demonstrating its effectiveness in detecting various infectious pathogens in the human body. The test has been successful in diagnosing neurological infections with an 86 percent success rate and detecting respiratory viruses with over 90 percent accuracy compared to traditional PCR tests.
This groundbreaking technology, recently recognized by the U.S. Food and Drug Administration (FDA), has the potential to improve care for neurological infections like meningitis and encephalitis. It also has the capability to swiftly identify new viral threats, enhancing disease control and prevention efforts.
Unlike conventional tests that can only detect a limited number of pathogens, this new genomic test analyzes the genetic material in patient samples to identify all present pathogens. By assessing the quantity of different pathogens in the sample, the test can predict disease severity and pinpoint the specific pathogen causing the infection.
Initially developed for analyzing cerebrospinal fluid (CSF) using metagenomic next-generation sequencing (mNGS), this technology has been utilized on thousands of patients with unexplained neurological symptoms. The automated mNGS process has also been applied to identify pneumonia-causing pathogens in respiratory fluid, showcasing the versatility and potential applications of this innovative test.
Dr. Charles Chiu, the senior study author and professor of laboratory medicine and infectious diseases at UCSF, highlighted the simplicity and effectiveness of the test, emphasizing its ability to streamline the diagnostic process and improve patient outcomes. The test has already made a significant impact in real-world cases, resolving previously undiagnosed infections and demonstrating superior performance in diagnosing neurologic infections.
As the technology evolves, particularly in respiratory testing, the goal is to expedite the testing process for faster results. The mNGS test has the potential to detect respiratory viruses, including those responsible for pandemics like SARS-CoV-2, within one day. Both the CSF and respiratory mNGS tests have received breakthrough device designation from the FDA, paving the way for further advancements and integration into clinical practice.
Source link
